Global T-cell Therapy Market Size, Trends & Analysis - Forecasts to 2029 By Therapy Type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based), By Process Step (Hematologic Malignancies [Lymphoma, Leukemia, and Myeloma], Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, and Others], and Others), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global T-cell therapy market is estimated to exhibit a CAGR of 36.1% from 2024 to 2029.
The primary factors propelling the market growth are the increasing prevalence of cancer and autoimmune diseases and the growing investment in immunotherapy research and development. As cancer rates rise, there is an urgent need for effective treatment options, making T-cell therapies a critical area of focus. These treatments provide a promising substitute for conventional medicines by using the body's immune system, especially T-cells, to target and eradicate cancerous cells. Additionally, autoimmune diseases, which affect millions worldwide, are prompting research into T-cell therapies that can modulate immune responses. The growing incidence of these conditions is leading to heightened demand for innovative therapies that provide more personalized and effective treatment strategies. As healthcare providers and patients increasingly recognize the potential of T-cell therapies in addressing these challenges, the market is expected to expand rapidly. For instance, the National Cancer Institute estimates that 9.7 million people died from cancer globally in 2022, and there were about 20 million new cases.
Increasing regulatory approvals for novel T-cell therapies along with the rising adoption of personalized medicine are expected to support the market growth. More T-cell therapies are entering the market as regulatory agencies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) accelerate their approval procedures, encouraging competition and innovation. This tendency motivates pharmaceutical companies to spend on research and development while also enhancing the legitimacy of T-cell treatments as effective therapy choices. With successful approvals of groundbreaking therapies, such as CAR-T cell treatments for specific cancers, healthcare providers are more willing to adopt these advanced therapies in clinical practice. Additionally, regulatory approvals often lead to expanded indications for existing therapies, further increasing their market potential. For instance, Yescarta, the first chimeric antigen receptor (CAR) T-cell therapy, was approved by the U.S. FDA in February 2022 for the initial treatment of relapsed or refractory large B-cell lymphoma (LBCL).
Advances in gene editing technologies coupled with the growing awareness and acceptance of immunotherapies propel market growth. Gene editing technologies enable researchers to modify T-cells at a genetic level, improving their ability to target and destroy cancer cells or modulate immune responses in autoimmune diseases. By allowing for the introduction of specific genes or the correction of mutations, gene editing has led to the development of more effective and personalized T-cell therapies. For instance, to increase the effectiveness of treatment modified T-cells can be made to express chimeric antigen receptors (CARs), which target tumor markers selectively. Furthermore, these innovations reduce the time and cost associated with developing new therapies, accelerating their path to clinical application.
There is a growing opportunity to explore combination therapies that integrate T-cell treatments with other modalities, such as chemotherapy or checkpoint inhibitors, potentially leading to synergistic effects and improved patient responses. Additionally, advances in delivery methods, such as engineered T-cell infusions or localized therapies, create opportunities for improving the efficacy and safety profiles of T-cell therapies, making them more appealing to both clinicians and patients.
However, the high costs associated with T-cell therapies and the intricate and time-consuming manufacturing processes impede market growth.
The CAR T-cell therapies segment is expected to hold the largest share of the market over the forecast period. CAR T-cell therapies have demonstrated significant efficacy in treating various hematological malignancies, particularly in relapsed or refractory cases. Clinical trials have shown high response rates and durable remissions, establishing these therapies as effective treatment options.
The T cell receptor (TCR)-based therapies segment is expected to be the fastest-growing segment in the market from 2024 to 2029. TCR treatments can be customized for each patient according to their distinct tumor antigen signatures, supporting the expanding personalized medicine movement. This customization enhances the likelihood of treatment efficacy and improves patient outcomes.
The hematologic malignancies segment is expected to hold the largest share of the market over the forecast period. Several CAR T-cell therapies specifically targeting hematologic cancers have received approvals from regulatory bodies, such as the FDA and EMA. These approvals boost confidence among healthcare providers and patients, driving further adoption within this segment.
The solid tumors segment is anticipated to be the fastest-growing segment in the market from 2024 to 2029. Solid tumors often express a variety of tumor-associated antigens, presenting opportunities for T-cell therapies to develop specific targeting strategies. This diversification allows for a broader application of T-cell therapies in different cancer types, driving growth in this segment.
North America is expected to be the largest region in the global market. Favorable regulatory pathways and strong support from agencies like the FDA promote the development and approval of T-cell therapies. This encourages companies to focus their efforts on bringing new therapies to market in the region.
Asia Pacific is anticipated to witness rapid growth during the forecast period. Governments and private sectors in Asia Pacific are significantly increasing investments in healthcare infrastructure and biotechnology. This financial support fosters the development and adoption of advanced therapies, including T-cell therapies.
Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, and Celgene Corporation among others, are some of the key players in the global T-cell therapy market.
Please note: This is not an exhaustive list of companies profiled in the report.
In August 2023, Astellas made a USD 50 million investment in Poseida's CAR T cell treatment. The agreement will grant Astellas exclusive negotiation and first refusal for licensing P-MUC1C-ALLO1 in solid tumors.
In January 2023, the California Institute for Regenerative Medicine (CIRM) invested $4 million in developing and testing a CAR T cell therapy that can be used to treat a variety of B-cell cancers, from leukemias to lymphomas.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL T-CELL THERAPY MARKET, BY Therapy Type
4.1 Introduction
4.2 T-cell Therapy Market: Therapy Type Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 CAR T-cell Therapy
4.4.1 CAR T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
4.5 T Cell Receptor (TCR)-based
4.5.1 T Cell Receptor (TCR)-based Market Estimates and Forecast, 2021-2029 (USD Million)
4.6 Tumor Infiltrating Lymphocytes (TIL)-based
4.6.1 Tumor Infiltrating Lymphocytes (TIL)-based Market Estimates and Forecast, 2021-2029 (USD Million)
5 GLOBAL T-CELL THERAPY MARKET, BY PROCESS STEP
5.1 Introduction
5.2 T-cell Therapy Market: Process Step Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Hematologic Malignancies[Lymphoma, Leukemia, and Myeloma]
5.4.1 Hematologic Malignancies[Lymphoma, Leukemia, and Myeloma] Market Estimates and Forecast, 2021-2029 (USD Million)
5.5 Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, and Others]
5.5.1 Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, and Others] Market Estimates and Forecast, 2021-2029 (USD Million)
5.6 Others
5.6.1 Others Market Estimates and Forecast, 2021-2029 (USD Million)
6 GLOBAL T-CELL THERAPY MARKET, BY REGION
6.1 Introduction
6.2 North America T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.1 By Therapy Type
6.2.2 By Process Step
6.2.3 By Country
6.2.3.1 U.S. T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.1.1 By Therapy Type
6.2.3.1.2 By Process Step
6.2.3.2 Canada T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.2.1 By Therapy Type
6.2.3.2.2 By Process Step
6.2.3.3 Mexico T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.3.1 By Therapy Type
6.2.3.3.2 By Process Step
6.3 Europe T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.1 By Therapy Type
6.3.2 By Process Step
6.3.3 By Country
6.3.3.1 Germany T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.1.1 By Therapy Type
6.3.3.1.2 By Process Step
6.3.3.2 U.K. T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.2.1 By Therapy Type
6.3.3.2.2 By Process Step
6.3.3.3 France T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.3.1 By Therapy Type
6.3.3.3.2 By Process Step
6.3.3.4 Italy T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.4.1 By Therapy Type
6.3.3.4.2 By Process Step
6.3.3.5 Spain T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.5.1 By Therapy Type
6.3.3.5.2 By Process Step
6.3.3.6 Netherlands T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Therapy Type
6.3.3.6.2 By Process Step
6.3.3.7 Rest of Europe T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Therapy Type
6.3.3.6.2 By Process Step
6.4 Asia Pacific T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.1 By Therapy Type
6.4.2 By Process Step
6.4.3 By Country
6.4.3.1 China T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.1.1 By Therapy Type
6.4.3.1.2 By Process Step
6.4.3.2 Japan T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.2.1 By Therapy Type
6.4.3.2.2 By Process Step
6.4.3.3 India T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.3.1 By Therapy Type
6.4.3.3.2 By Process Step
6.4.3.4 South Korea T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.4.1 By Therapy Type
6.4.3.4.2 By Process Step
6.4.3.5 Singapore T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.5.1 By Therapy Type
6.4.3.5.2 By Process Step
6.4.3.6 Malaysia T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Therapy Type
6.4.3.6.2 By Process Step
6.4.3.7 Thailand T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Therapy Type
6.4.3.6.2 By Process Step
6.4.3.8 Indonesia T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.7.1 By Therapy Type
6.4.3.7.2 By Process Step
6.4.3.9 Vietnam T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.8.1 By Therapy Type
6.4.3.8.2 By Process Step
6.4.3.10 Taiwan T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.10.1 By Therapy Type
6.4.3.10.2 By Process Step
6.4.3.11 Rest of Asia Pacific T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.11.1 By Therapy Type
6.4.3.11.2 By Process Step
6.5 Middle East and Africa T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.1 By Therapy Type
6.5.2 By Process Step
6.5.3 By Country
6.5.3.1 Saudi Arabia T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.1.1 By Therapy Type
6.5.3.1.2 By Process Step
6.5.3.2 U.A.E. T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.2.1 By Therapy Type
6.5.3.2.2 By Process Step
6.5.3.3 Israel T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.3.1 By Therapy Type
6.5.3.3.2 By Process Step
6.5.3.4 South Africa T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.4.1 By Therapy Type
6.5.3.4.2 By Process Step
6.5.3.5 Rest of Middle East and Africa T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.5.1 By Therapy Type
6.5.3.5.2 By Process Step
6.6 Central and South America T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.1 By Therapy Type
6.6.2 By Process Step
6.6.3 By Country
6.6.3.1 Brazil T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.1.1 By Therapy Type
6.6.3.1.2 By Process Step
6.6.3.2 Argentina T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.2.1 By Therapy Type
6.6.3.2.2 By Process Step
6.6.3.3 Chile T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Therapy Type
6.6.3.3.2 By Process Step
6.6.3.3 Rest of Central and South America T-cell Therapy Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Therapy Type
6.6.3.3.2 By Process Step
7 COMPETITIVE LANDCAPE
7.1 Company Market Share Analysis
7.2 Four Quadrant Positioning Matrix
7.2.1 Market Leaders
7.2.2 Market Visionaries
7.2.3 Market Challengers
7.2.4 Niche Market Players
7.3 Vendor Landscape
7.3.1 North America
7.3.2 Europe
7.3.3 Asia Pacific
7.3.4 Rest of the World
7.4 Company Profiles
7.4.1 Novartis AG
7.4.1.1 Business Description & Financial Analysis
7.4.1.2 SWOT Analysis
7.4.1.3 Products & Services Offered
7.4.1.4 Strategic Initiatives
7.4.2 Merck KGaA
7.4.2.1 Business Description & Financial Analysis
7.4.2.2 SWOT Analysis
7.4.2.3 Products & Services Offered
7.4.2.4 Strategic Initiatives
7.4.3 Gilead Sciences Inc.
7.4.3.1 Business Description & Financial Analysis
7.4.3.2 SWOT Analysis
7.4.3.3 Products & Services Offered
7.4.3.4 Strategic Initiatives
7.4.4 TCR2 Therapeutics Inc.
7.4.4.1 Business Description & Financial Analysis
7.4.4.2 SWOT Analysis
7.4.4.3 Products & Services Offered
7.4.4.4 Strategic Initiatives
7.4.5 Bluebird Bio Inc.
7.4.5.1 Business Description & Financial Analysis
7.4.5.2 SWOT Analysis
7.4.5.3 Products & Services Offered
7.4.5.4 Strategic Initiatives
7.4.6 SORRENTO THERAPEUTICS
7.4.6.1 Business Description & Financial Analysis
7.4.6.2 SWOT Analysis
7.4.6.3 Products & Services Offered
7.4.6.4 Strategic Initiatives
7.4.7 Fate Therapeutics
7.4.7.1 Business Description & Financial Analysis
7.4.7.2 SWOT Analysis
7.4.7.3 Products & Services Offered
7.4.7.4 Strategic Initiatives
7.4.8 Pfizer Inc.
7.4.8.1 Business Description & Financial Analysis
7.4.8.2 SWOT Analysis
7.4.8.3 Products & Services Offered
7.4.8.4 Strategic Initiatives
7.4.9 Amgen
7.4.9.1 Business Description & Financial Analysis
7.4.9.2 SWOT Analysis
7.4.9.3 Products & Services Offered
7.4.9.4 Strategic Initiatives
7.4.10 Celgene Corporation
7.4.10.1 Business Description & Financial Analysis
7.4.10.2 SWOT Analysis
7.4.10.3 Products & Services Offered
7.4.10.4 Strategic Initiatives
7.4.11 Other Companies
7.4.11.1 Business Description & Financial Analysis
7.4.11.2 SWOT Analysis
7.4.11.3 Products & Services Offered
7.4.11.4 Strategic Initiatives
8 RESEARCH METHODOLOGY
8.1 Market Introduction
8.1.1 Market Definition
8.1.2 Market Scope & Segmentation
8.2 Information Procurement
8.2.1 Secondary Research
8.2.1.1 Purchased Databases
8.2.1.2 GMEs Internal Data Repository
8.2.1.3 Secondary Resources & Third Party Perspectives
8.2.1.4 Company Information Sources
8.2.2 Primary Research
8.2.2.1 Various Type of Respondents for Primary Interviews
8.2.2.2 Number of Interviews Conducted throughout the Research Process
8.2.2.3 Primary Stakeholders
8.2.2.4 Discussion Guide for Primary Participants
8.2.3 Expert Panels
8.2.3.1 Expert Panels Across 30+ Industry
8.2.4 Paid Local Experts
8.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
8.3 Market Estimation
8.3.1 Top-Down Approach
8.3.1.1 Macro-Economic Indicators Considered
8.3.1.2 Micro-Economic Indicators Considered
8.3.2 Bottom Up Approach
8.3.2.1 Company Share Analysis Approach
8.3.2.2 Estimation of Potential Product Sales
8.4 Data Triangulation
8.4.1 Data Collection
8.4.2 Time Series, Cross Sectional & Panel Data Analysis
8.4.3 Cluster Analysis
8.5 Analysis and Output
8.5.1 Inhouse AI Based Real Time Analytics Tool
8.5.2 Output From Desk & Primary Research
8.6 Research Assumptions & Limitations
8.6.1 Research Assumptions
8.6.2 Research Limitations
LIST OF TABLES
1 Global T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
2 CAR T-cell Therapy Market, By Region, 2021-2029 (USD Million)
3 T Cell Receptor (TCR)-based Market, By Region, 2021-2029 (USD Million)
4 Tumor Infiltrating Lymphocytes (TIL)-based Market, By Region, 2021-2029 (USD Million)
5 Global T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
6 Hematologic Malignancies[Lymphoma, Leukemia, and Myeloma] Market, By Region, 2021-2029 (USD Million)
7 Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, and Others] Market, By Region, 2021-2029 (USD Million)
8 Others Market, By Region, 2021-2029 (USD Million)
9 Regional Analysis, 2021-2029 (USD Million)
10 North America T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
11 North America T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
12 North America T-cell Therapy Market, By COUNTRY, 2021-2029 (USD Million)
13 U.S. T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
14 U.S. T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
15 Canada T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
16 Canada T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
17 Mexico T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
18 Mexico T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
19 Europe T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
20 Europe T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
21 EUROPE T-cell Therapy Market, By COUNTRY, 2021-2029 (USD Million)
22 Germany T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
23 Germany T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
24 U.K. T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
25 U.K. T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
26 France T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
27 France T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
28 Italy T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
29 Italy T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
30 Spain T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
31 Spain T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
32 Netherlands T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
33 Netherlands T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
34 Rest Of Europe T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
35 Rest Of Europe T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
36 Asia Pacific T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
37 Asia Pacific T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
38 ASIA PACIFIC T-cell Therapy Market, By COUNTRY, 2021-2029 (USD Million)
39 China T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
40 China T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
41 Japan T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
42 Japan T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
43 India T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
44 India T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
45 South Korea T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
46 South Korea T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
47 Singapore T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
48 Singapore T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
49 Thailand T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
50 Thailand T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
51 Malaysia T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
52 Malaysia T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
53 Indonesia T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
54 Indonesia T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
55 Vietnam T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
56 Vietnam T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
57 Taiwan T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
58 Taiwan T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
59 Rest of APAC T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
60 Rest of APAC T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
61 Middle East and Africa T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
62 Middle East and Africa T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
63 MIDDLE EAST & AFRICA T-cell Therapy Market, By COUNTRY, 2021-2029 (USD Million)
64 Saudi Arabia T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
65 Saudi Arabia T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
66 UAE T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
67 UAE T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
68 Israel T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
69 Israel T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
70 South Africa T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
71 South Africa T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
72 Rest Of Middle East and Africa T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
73 Rest Of Middle East and Africa T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
74 Central and South America T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
75 Central and South America T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
76 CENTRAL AND SOUTH AMERICA T-cell Therapy Market, By COUNTRY, 2021-2029 (USD Million)
77 Brazil T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
78 Brazil T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
79 Chile T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
80 Chile T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
81 Argentina T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
82 Argentina T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
83 Rest Of Central and South America T-cell Therapy Market, By Therapy Type, 2021-2029 (USD Million)
84 Rest Of Central and South America T-cell Therapy Market, By Process Step, 2021-2029 (USD Million)
85 Novartis AG: Products & Services Offering
86 Merck KGaA: Products & Services Offering
87 Gilead Sciences Inc.: Products & Services Offering
88 TCR2 Therapeutics Inc.: Products & Services Offering
89 Bluebird Bio Inc.: Products & Services Offering
90 SORRENTO THERAPEUTICS: Products & Services Offering
91 Fate Therapeutics: Products & Services Offering
92 Pfizer Inc.: Products & Services Offering
93 Amgen, Inc: Products & Services Offering
94 Celgene Corporation: Products & Services Offering
95 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global T-cell Therapy Market Overview
2 Global T-cell Therapy Market Value From 2021-2029 (USD Million)
3 Global T-cell Therapy Market Share, By Therapy Type (2023)
4 Global T-cell Therapy Market Share, By Process Step (2023)
5 Global T-cell Therapy Market, By Region (Asia Pacific Market)
6 Technological Trends In Global T-cell Therapy Market
7 Four Quadrant Competitor Positioning Matrix
8 Impact Of Macro & Micro Indicators On The Market
9 Impact Of Key Drivers On The Global T-cell Therapy Market
10 Impact Of Challenges On The Global T-cell Therapy Market
11 Porter’s Five Forces Analysis
12 Global T-cell Therapy Market: By Therapy Type Scope Key Takeaways
13 Global T-cell Therapy Market, By Therapy Type Segment: Revenue Growth Analysis
14 CAR T-cell Therapy Market, By Region, 2021-2029 (USD Million)
15 T Cell Receptor (TCR)-based Market, By Region, 2021-2029 (USD Million)
16 Tumor Infiltrating Lymphocytes (TIL)-based Market, By Region, 2021-2029 (USD Million)
17 Global T-cell Therapy Market: By Process Step Scope Key Takeaways
18 Global T-cell Therapy Market, By Process Step Segment: Revenue Growth Analysis
19 Hematologic Malignancies[Lymphoma, Leukemia, and Myeloma] Market, By Region, 2021-2029 (USD Million)
20 Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, and Others] Market, By Region, 2021-2029 (USD Million)
21 Others Market, By Region, 2021-2029 (USD Million)
22 Regional Segment: Revenue Growth Analysis
23 Global T-cell Therapy Market: Regional Analysis
24 North America T-cell Therapy Market Overview
25 North America T-cell Therapy Market, By Therapy Type
26 North America T-cell Therapy Market, By Process Step
27 North America T-cell Therapy Market, By Country
28 U.S. T-cell Therapy Market, By Therapy Type
29 U.S. T-cell Therapy Market, By Process Step
30 Canada T-cell Therapy Market, By Therapy Type
31 Canada T-cell Therapy Market, By Process Step
32 Mexico T-cell Therapy Market, By Therapy Type
33 Mexico T-cell Therapy Market, By Process Step
34 Four Quadrant Positioning Matrix
35 Company Market Share Analysis
36 Novartis AG: Company Snapshot
37 Novartis AG: SWOT Analysis
38 Novartis AG: Geographic Presence
39 Merck KGaA: Company Snapshot
40 Merck KGaA: SWOT Analysis
41 Merck KGaA: Geographic Presence
42 Gilead Sciences Inc.: Company Snapshot
43 Gilead Sciences Inc.: SWOT Analysis
44 Gilead Sciences Inc.: Geographic Presence
45 TCR2 Therapeutics Inc.: Company Snapshot
46 TCR2 Therapeutics Inc.: Swot Analysis
47 TCR2 Therapeutics Inc.: Geographic Presence
48 Bluebird Bio Inc.: Company Snapshot
49 Bluebird Bio Inc.: SWOT Analysis
50 Bluebird Bio Inc.: Geographic Presence
51 SORRENTO THERAPEUTICS: Company Snapshot
52 SORRENTO THERAPEUTICS: SWOT Analysis
53 SORRENTO THERAPEUTICS: Geographic Presence
54 Fate Therapeutics : Company Snapshot
55 Fate Therapeutics : SWOT Analysis
56 Fate Therapeutics : Geographic Presence
57 Pfizer Inc.: Company Snapshot
58 Pfizer Inc.: SWOT Analysis
59 Pfizer Inc.: Geographic Presence
60 Amgen, Inc.: Company Snapshot
61 Amgen, Inc.: SWOT Analysis
62 Amgen, Inc.: Geographic Presence
63 Celgene Corporation: Company Snapshot
64 Celgene Corporation: SWOT Analysis
65 Celgene Corporation: Geographic Presence
66 Other Companies: Company Snapshot
67 Other Companies: SWOT Analysis
68 Other Companies: Geographic Presence
The Global T-cell Therapy Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the T-cell Therapy Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS